Acadia Pharmaceuticals Inc. ACAD
18.75 USD +0.61 (+3.36%)
At closeNov 13, 2026, 7:29 PM EST
18.79 +0.04 +0.21%
After hours · Nov 13, 7:29 PM ET
18.00 Day range 18.76
16.50 52-week range 30.57
- YTD
- -29.80%
- 1 year
- -20.69%
News
benzinga.com Morgan Stanley Maintains Equal-Weight on Acadia Pharmaceuticals, Lowers Price Target to $24 Morgan Stanley analyst Jeffrey Hung maintains Acadia Pharmaceuticals (NASDAQ:ACAD) with a Equal-Weight and lowers the price target from $28 to $24.
defenseworld.net ACADIA Pharmaceuticals Inc. $ACAD Shares Purchased by Allspring Global Investments Holdings LLC Allspring Global Investments Holdings LLC lifted its stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) by 35.1% during the third quarter, according to the company in its most recent…
businesswire.com Acadia Pharmaceuticals Comments on Federal Circuit Oral Argument in NUPLAZID® Formulation Patent Appeal SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today reported that oral arguments were held before the U.S. Court of Appeals for the Federal Circuit in the appeal of the U.S.…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Karyopharm Therapeutics (NASDAQ:KPTI) stock moved upwards by 10.0% to $0.04 during Monday's after-market session. The company's market cap stands at $1.2 million. Fractyl Health (NASDAQ:GUTS)…
benzinga.com Canaccord Genuity Maintains Buy on Acadia Pharmaceuticals, Raises Price Target to $38 Canaccord Genuity analyst Sumant Kulkarni maintains Acadia Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $36 to $38.
benzinga.com DraftKings Posts Downbeat Q3 Results, Joins Atlassian, Natera And Other Big Stocks Moving Lower In Friday’s Pre-Market Session Stock futures mixed as DraftKings plunged 21% after earnings missed estimates and FY26 guidance was cut; several other stocks also fell premarket.
benzinga.com RBC Capital Maintains Outperform on Acadia Pharmaceuticals, Raises Price Target to $38 RBC Capital analyst Brian Abrahams maintains Acadia Pharmaceuticals (NASDAQ:ACAD) with a Outperform and raises the price target from $36 to $38.
seekingalpha.com Acadia Pharmaceuticals Inc. (ACAD) Q3 2026 Earnings Call Transcript Acadia Pharmaceuticals Inc. (ACAD) Q3 2026 Earnings Call Transcript
zacks.com Acadia Pharmaceuticals (ACAD) Tops Q3 Earnings and Revenue Estimates Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.26 per share a year ago.
marketbeat.com What ACADIA Pharmaceuticals (ACAD) Said on Its Q3 Earnings Call ACADIA Pharmaceuticals NASDAQ: ACAD reported third-quarter 2026 revenue of $342 million, up 22% from a year earlier on an adjusted basis, as demand for its Rett syndrome treatment DAYBUE and…
benzinga.com ACADIA Pharmaceuticals Q3 2026 Earnings Call Transcript ACADIA Pharmaceuticals (NASDAQ:ACAD) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com ACADIA Pharmaceuticals Narrows FY2026 Sales Guidance from $1.240B-$1.300B to $1.265B-$1.295B vs $1.272B Est ACADIA Pharmaceuticals (NASDAQ:ACAD) narrows FY2026 sales outlook from $1.240 billion-$1.300 billion to $1.265 billion-$1.295 billion vs $1.272 billion estimate.
businesswire.com Acadia Pharmaceuticals Reports Third Quarter 2026 Financial Results SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the third quarter ended September 30, 2026. “Acadia delivered a strong third quarter,…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are…
businesswire.com Acadia Pharmaceuticals to Participate in the UBS Global Biopharma Conference 2026 SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the UBS Global Biopharma Conference 2026 on Tuesday, November 17,…
zacks.com Earnings Preview: Acadia Pharmaceuticals (ACAD) Q3 Earnings Expected to Decline Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. (“Acadia” or the “Company”) (NASDAQ: ACAD). Such investors are…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD NEW YORK, Oct. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are…
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. (“Acadia” or the “Company”) (NASDAQ: ACAD). Such investors are…
defenseworld.net Needham & Company LLC Reaffirms Buy Rating for ACADIA Pharmaceuticals (NASDAQ:ACAD) ACADIA Pharmaceuticals (NASDAQ: ACAD - Get Free Report)'s stock had its "buy" rating reissued by investment analysts at Needham and Company LLC in a research note issued on Monday, Benzinga reports.…
benzinga.com Needham Reiterates Buy on Acadia Pharmaceuticals, Maintains $35 Price Target Needham analyst Ami Fadia reiterates Acadia Pharmaceuticals (NASDAQ:ACAD) with a Buy and maintains $35 price target.
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are…
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. (“Acadia” or the “Company”) (NASDAQ: ACAD). Such investors are…- benzinga.com UBS Downgrades Acadia Pharmaceuticals to Neutral, Lowers Price Target to $23 UBS analyst Ashwani Verma downgrades Acadia Pharmaceuticals (NASDAQ:ACAD) from Buy to Neutral and lowers the price target from $49 to $23.
zacks.com Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects? ACAD's Nuplazid and Daybue drive revenue growth, with rising demand, new formulations and European expansion offering opportunities amid growing competition.
defenseworld.net Reviewing ACADIA Pharmaceuticals (NASDAQ:ACAD) and C4 Therapeutics (NASDAQ:CCCC) C4 Therapeutics (NASDAQ: CCCC - Get Free Report) and ACADIA Pharmaceuticals (NASDAQ: ACAD - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the…
zacks.com 4 CNS Drug Stocks Worth Watching This World Mental Health Day AXSM, NBIX, ALKS and ACAD are advancing CNS treatments for mental health disorders, with growing product sales, pipeline progress and new growth opportunities.
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are…
benzinga.com RBC Capital Maintains Outperform on Acadia Pharmaceuticals, Lowers Price Target to $36 RBC Capital analyst Brian Abrahams maintains Acadia Pharmaceuticals (NASDAQ:ACAD) with a Outperform and lowers the price target from $37 to $36.
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. (“Acadia” or the “Company”) (NASDAQ: ACAD). Such investors are…- benzinga.com Acadia Pharmaceuticals Announces USPTO Issued Notice Of Allowance For U.S. Patent Application No. 17/590,496, Titled “Methods and Compositions for Treatment of Rett Syndrome.” https://acadia.com/en-us/media/news-releases/acadia-pharmaceuticals-announces-allowance-of-u-s--patent-covering-weight-banded-dosing-of-trofinetide-extending-u-s--patent-protections-to-march-2041
benzinga.com Deutsche Bank Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $31 Deutsche Bank analyst David Hoang maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $38 to $31.- benzinga.com HC Wainwright & Co. Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $33 HC Wainwright & Co. analyst Ananda Ghosh maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $37 to $33.
benzinga.com AMD To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Friday Analysts cut targets for GWW, IE and COST, while raising targets for OKTA, AXGN, ZS and DRI; ratings remained unchanged.- benzinga.com Citizens Maintains Market Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $33 Citizens analyst Jason N. Butler maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Market Outperform and lowers the price target from $36 to $33.
- benzinga.com BMO Capital Maintains Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $34 BMO Capital analyst Evan David Seigerman maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperform and lowers the price target from $36 to $34.
- benzinga.com Needham Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $35 Needham analyst Ami Fadia maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $41 to $35.
- benzinga.com Citigroup Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $33 Citigroup analyst Yigal Nochomovitz maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $40 to $33.
benzinga.com Acadia Drug Misses Primary Goal in Alzheimer’s Related Psychosis Acadia Pharmaceuticals reports Phase 2 remlifanserin trial results for Alzheimer’s psychosis and plans to move into Phase 3.
benzinga.com Crude Oil Rises Over 4%; Darden Earnings Miss Views U.S. stocks fell Thursday: Dow -0.7%, S&P 500 -0.46%, Nasdaq -0.7%. Oil jumped 4.4%; Darden missed estimates, while APUS surged 163%.
benzinga.com Needham Reiterates Buy on ACADIA Pharmaceuticals, Maintains $41 Price Target Needham analyst Ami Fadia reiterates ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and maintains $41 price target.
benzinga.com Acadia’s Remlifanserin Advances Toward Phase 3 In Alzheimer’s Psychosis Despite Narrow Miss On Primary Endpoint -- Meaningful and consistent efficacy trends across endpoints support continuing with Phase 3 development of 60 mg once daily remlifanserin in ADP, with demonstrated evidence of dose effect--…
benzinga.com Acadia Pharmaceuticals Receives Preliminary Court Approval Of Settlement Of Kanner Et Al. V. Biggar Et Al. Derivative Action On August 24, 2026, the United States District Court for the Southern District of California (the "Court") preliminarily approved the settlement ("Settlement") of the stockholder derivative action- benzinga.com Deutsche Bank Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $38 Deutsche Bank analyst David Hoang maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $37 to $38.
- benzinga.com Morgan Stanley Maintains Equal-Weight on ACADIA Pharmaceuticals, Raises Price Target to $28 Morgan Stanley analyst Jeffrey Hung maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Equal-Weight and raises the price target from $27 to $28.
- benzinga.com Citigroup Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $40 Citigroup analyst Yigal Nochomovitz maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $39 to $40.
- benzinga.com UBS Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $49 UBS analyst Ashwani Verma maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $45 to $49.
- benzinga.com Needham Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $41 Needham analyst Ami Fadia maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $38 to $41.
- benzinga.com Citigroup Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $39 Citigroup analyst Yigal Nochomovitz maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $35 to $39.
- benzinga.com Oppenheimer Maintains Perform on ACADIA Pharmaceuticals, Raises Price Target to $25 Oppenheimer analyst Matthew Hershenhorn maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Perform and raises the price target from $23 to $25.